Viking Therapeutics Surges 38% on Obesity Drug Data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, which the source notes shows promise for weight-loss maintenance.
- VKTX spiked 38% in premarket trading following the announcement, while Eli Lilly and Novo Nordisk (referenced as "Novo") shares fell, per Investor's Business Daily's headline framing.
Why it matters: Viking's positive maintenance data positions VK2735 as a credible new entrant in the GLP-1 obesity drug market, with VKTX's 38% premarket surge and the simultaneous drop in Eli Lilly and Novo Nordisk shares reflecting how quickly investors repriced the competitive landscape.
Ask SkimNews
